Published in J Pharmacokinet Biopharm on October 01, 1986
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn (2002) 1.40
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol (2005) 1.02
Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn (2007) 0.93
Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling. J Pharmacokinet Pharmacodyn (2007) 0.89
Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm Drug Dispos (2007) 0.85
Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats. Anal Chem (2014) 0.81
LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed (1983) 4.02
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther (1973) 1.74
Prednisone side-effects and serum-protein levels. A collaborative study. Lancet (1971) 1.67
Contribution of cigarette smoking to cadmium accumulation in man. Lancet (1972) 1.63
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Effect of smoking on theophylline disposition. Clin Pharmacol Ther (1976) 1.58
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol (1998) 1.46
Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.43
Esophageal motor abnormalities in children with gastroesophageal reflux and peptic esophagitis. J Pediatr (1986) 1.43
Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2008) 1.42
Theophylline disposition in obesity. Clin Pharmacol Ther (1978) 1.42
Reduction of K+ uptake in glia prevents long-term depression maintenance and causes epileptiform activity. J Neurosci (1997) 1.40
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother (1990) 1.38
Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther (2001) 1.38
Comparison of ampicillin and hetacillin pharmacokinetics in man. J Pharm Sci (1973) 1.35
Theophylline secretion into breast milk. Pediatrics (1976) 1.35
Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci (1998) 1.34
Theophylline pharmacokinetics in premature infants with apnea. J Pediatr (1976) 1.34
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Cadmium accumulation im man: influence of smoking, occupation, alcoholic habit and disease. J Chronic Dis (1972) 1.27
Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther (1999) 1.27
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci (1998) 1.26
Heterogeneity of astrocyte resting membrane potentials and intercellular coupling revealed by whole-cell and gramicidin-perforated patch recordings from cultured neocortical and hippocampal slice astrocytes. J Neurosci (1997) 1.25
Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev (1979) 1.23
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J Chromatogr (1988) 1.22
Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm (1999) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet (2000) 1.20
Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. Antimicrob Agents Chemother (1992) 1.20
Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci (1971) 1.19
Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci (1984) 1.18
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci (1993) 1.17
Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.17
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm (1978) 1.16
Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother (1985) 1.15
Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet (1996) 1.14
Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther (1975) 1.11
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Pharmacokinetics of a water-soluble fullerene in rats. Antimicrob Agents Chemother (1996) 1.10
Fluorometric analysis of ampicillin in biological fluids. J Pharm Sci (1971) 1.09
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09
Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. Br J Obstet Gynaecol (1993) 1.07
Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int (2000) 1.07
Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med (1977) 1.07
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Pharmacokinetics of theophylline in hepatic disease. Chest (1978) 1.07
Precipitation of diazepam from intravenous preparations. JAMA (1973) 1.07
Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med (1978) 1.05
Frequency-dependent changes in cerebral blood flow and evoked potentials during somatosensory stimulation in the rat. Brain Res (1999) 1.05
Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother (1982) 1.05
Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr (1979) 1.04
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther (1988) 1.04
Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm (1981) 1.03
Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res Hum Retroviruses (1999) 1.03
Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm (1991) 1.03
Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm (1994) 1.02
Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. J Chromatogr B Biomed Appl (1994) 1.01
Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol (1998) 1.01
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol (1992) 1.00
Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm (1976) 0.99
Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther (1982) 0.99
Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol (1971) 0.99
Role of baseline parameters in determining indirect pharmacodynamic responses. J Pharm Sci (1999) 0.99
Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal Biochem (1993) 0.98
Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy (1990) 0.98
Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm (1975) 0.98
Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther (1997) 0.98
Pharmacokinetics of antibiotic absorption in coeliac disease. J Antimicrob Chemother (1976) 0.97
Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab (1983) 0.97
Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos (2000) 0.97
Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob Agents Chemother (1996) 0.97
Monitoring prednisone and prednisolone. Ther Drug Monit (1980) 0.97
Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone. Pharm Res (1992) 0.97
Comparative tissue accumulation of gentamicin and tobramycin in patients. J Antimicrob Chemother (1978) 0.96
Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys. Antimicrob Agents Chemother (1996) 0.96
Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther (1986) 0.96
Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm (1995) 0.96
Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res (1998) 0.96
Drug compliance and unreported drugs in the elderly. J Am Geriatr Soc (1989) 0.96
Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J Pharmacol Exp Ther (1998) 0.95
Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther (1991) 0.95
Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. J Pharm Sci (1989) 0.95
Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos (1981) 0.95